FDA, EU Likely to Boost Use of Special Designations in 2013: Tufts

January 14, 2013
U.S. and EU regulators hope to increase the use of special designations, such as fast track, priority review and accelerated approval, to speed approvals of drugs for non-cancer diseases that are rare and/or life-threatening, according to a new Tufts report. Regulators want to approve these products at the same levels oncology drugs enjoyed between 2007 and 2011.
Washington Drug Letter